Erythropoiesis-stimulating agents: Friends or foes?

Transfusion

Volumn 53, Issue 9, 2013, Pages 1867-1872

  Shander, Aryeh ^a   Ozawa, Sherri ^b   Gross, Irwin ^c   Henry, David ^d  

^a Anesthesiology and Critical Care Medicine   (United States)

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^c EASTERN MAINE MEDICAL CENTER   (United States)

^d PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; APROTININ; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE;

ANAPHYLAXIS; ANEMIA; BLEEDING; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; DRUG COST; DRUG SAFETY; HOSPITALIZATION; HUMAN; PRACTICE GUIDELINE; RECOMBINANT DNA TECHNOLOGY; REVIEW; TREATMENT RESPONSE;

BLOOD TRANSFUSION; ERYTHROPOIETIN; FEMALE; HUMANS; MALE;

EID: 84883861057     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12328     Document Type: Review

References (42)

1. Benoist B, McLean E, Cogswell M, Egli I,. Worldwide prevalence of anaemia 1993-2005. Geneva: World Health Organization; 2008.
2. Spence RK,. Medical and economic impact of anemia in hospitalized patients. Am J Health Syst Pharm 2007; 64: S3-10.
3. Murray TH,. The poisoned gift: AIDS and blood. Milbank Q 1990; 68: 205-225.
4. Shander A, Javidroozi M, Perelman S, Puzio T, Lobel G,. From bloodless surgery to patient blood management. Mt Sinai J Med 2012; 79: 56-65.
5. Goodnough LT, Shander A,. Patient blood management. Anesthesiology 2012; 116: 1367-1376.
6. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M,. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
7. Whoriskey P,. Anemia drugs made billions, but at what cost? The Washington Post, July 19, 2012.
8. Unger EF, Thompson AM, Blank MJ, Temple R,. Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010; 362: 189-192.
9. Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ,. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care. Pharmacotherapy 2008; 28: 1S-15S.
10. Manns BJ, Tonelli M,. The new FDA labeling for ESA-implications for patients and providers. Clin J Am Soc Nephrol 2012; 7: 348-353.
11. Singh AK,. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis 2008; 52: S5-13.
12. Kang RY, Lee J, Lee YH, Lee HS, Jeong JH, Lee YJ,. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea. Int J Clin Pharm 2012; 34: 651-657.
13. Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ,. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients. Pharmacoepidemiol Drug Saf 2012; 21: 857-864.
14. Sack K,. Unintended consequence for dialysis patients as drug rule changes. New York Times, May 11, 2013.
15. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R,. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331.
16. Meybohm P, Herrmann E, Nierhoff J, Zacharowski K,. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and epsilon-aminocaproic acid-a meta-analysis of randomised and observational trials of over 30,000 patients. PLoS ONE 2013; 8: e58009.
17. D'Ambra MN, Gray RJ, Hillman R, Jones JW, Kim HC, Rawitscher R, Schnaper H, Szymanski I, Vlahakes GJ, Kaplan D, Lynch KE, Guilfoyle M, Abels RI,. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64: 1686-1693.
18. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD,. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116: 2544-2552.
19. Shander A, Puzio T, Javidroozi M,. Variability in transfusion practice and effectiveness of strategies to improve it. J Cardiothorac Vasc Anesth 2012; 26: 541-544.
20. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J,. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;(12): CD003407.
21. Glynn SA, Busch MP, Dodd RY, Katz LM, Stramer SL, Klein HG, Simmons G, Kleinman SH, Shurin SB,. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013; 53: 438-454.
22. Shander A, Javidroozi M, Ozawa S, Hare GM,. What is really dangerous: anaemia or transfusion? Br J Anaesth 2011; 107 Suppl 1: i41-59.
23. Hofmann A, Farmer S, Towler SC,. Strategies to preempt and reduce the use of blood products: an Australian perspective. Curr Opin Anaesthesiol 2012; 25: 66-73.
24. Theusinger OM, Felix C, Spahn DR,. Strategies to reduce the use of blood products: a European perspective. Curr Opin Anaesthesiol 2012; 25: 59-65.
25. Goodnough LT, Shander AS,. Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine. Am J Hematol 2010; 85: 835-837.
26. Doodeman HJ, van Haelst IM, Egberts TC, Bennis M, Traast HS, van Solinge WW, Kalkman CJ, van Klei WA,. The effect of a preoperative erythropoietin protocol as part of a multifaceted blood management program in daily clinical practice. Transfusion 2013; 53: 1930-1939.
27. Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, Monk TG, Ozier Y, Slappendel R, Szpalski M,. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13-22.
28. Auerbach M, Ballard H,. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010: 338-347.
29. Shander A, Spence RK, Auerbach M,. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 2010; 50: 719-732.
30. Kotze A, Carter LA, Scally AJ,. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. Br J Anaesth 2012; 108: 943-952.
31. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD,. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 2011; 161: 822-831.
32. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF,. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
33. Carson JL, Carless PA, Hebert PC,. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;(4): CD002042.
34. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA,. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27: 2838-2847.
35. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J,. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer 2012; 76: 478-485.
36. Singh AK,. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens 2010; 19: 420-424.
37. Maiese K, Li F, Chong ZZ,. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
38. Basora M, Fita G, Matute P, Díaz-Ricart M,. Safety concerns about perisurgical epoetin treatment: should we add antiplatelet drugs to perisurgical epoetin alfa treatment? J Cardiothorac Vasc Anesth 2007; 21: 623-624.
39. Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A,. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368: 307-319.
40. Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S,. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368: 320-332.
41. Sabol VK, Resnick B, Galik E, Gruber-Baldini AL, Gonce MP, Hicks GE,. Anemia evaluation and management in nursing home residents. West J Nurs Res 2010; 32: 447-461.
42. Smith RE Jr,. The clinical and economic burden of anemia. Am J Manag Care 2010; 16 Suppl Issues: S59-66.